Hepatic veno-occlusive disease (HVOD) following bone marrow transplantation is potentially fatal. Criteria for diagnosis and starting treatment are mainly based on adult studies. Recombinant tissue plasminogen activator (rtPA) has been used with variable success. rtPA and heparin were given to 12 children (nine with immunodeficiency, two malignancy, one thalassaemia) with moderate to severe HVOD. Of the 12, 10 responded with a fall in bilirubin concentration; eight survived with complete resolution of HVOD. Four of the five patients with associated multiorgan failure (MOF) died despite rtPA treatment. One child suffered significant, and one minor, bleeding during rtPA treatment. A scoring system for quantifying the severity of HVOD in children is proposed, incorporating the criteria used to diagnose HVOD, risk factors for its development and also parameters reflective of the patient's general condition. This will facilitate early diagnosis and management of those cases which, if not treated promptly, are likely to deteriorate with an adverse outcome. Our experience suggests rtPA and heparin are an effective treatment for HVOD in children, with relatively little toxicity provided therapy is started before MOF develops.
Introduction
Hepatic veno-occlusive disease (HVOD) is a common complication following BMT conditioning regimens that incorporate alkylating agents, and when severe, carries a high morbidity and mortality. The pathogenesis and pathophysiology of HVOD is poorly understood. Some reports suggest that HVOD is due to nonthrombotic occlusion of the small hepatic veins 1 and others point to it being due to thrombotic occlusion. 2 Heparin, urokinase, prostaglandin E1 and ursodeoxycholic acid have all been used as prophylaxis, but none appear consistently effective in significantly reducing the incidence of severe HVOD.
Diagnostic criteria and predictors of outcome for HVOD have been derived mainly from studies of adult patients treated with specific conditioning protocols comprising cyclophosphamide (CY) and total body irradiation, or CY and busulphan. 3 Lack of data on children has led to the extrapolation of adult guidelines to paediatric practice. Furthermore, such guidelines incorporate criteria assessed by subjective clinical observations (eg hepatomegaly) with their inherent variability especially in children. The severity of HVOD may be defined retrospectively 4 by the outcome. Those patients with a self-limiting illness requiring no treatment have mild HVOD, those whose HVOD resolves with supportive treatment such as diuretics and analgesics have moderate HVOD, and patients who die of HVOD or whose HVOD does not resolve by 100 days post-BMT have severe HVOD. There is no consensus as to the best treatment of HVOD. Currently, recombinant tissue plasminogen activator (rtPA) and defibrotide seem the most promising treatments. 5, 6 However, there is limited data on the use of rtPA in children and virtually none concerning defibrotide. Miniero et al 7 have shown improved outcome if HVOD is diagnosed and treated promptly with rtPA once two out of the three McDonald 4 criteria are fulfilled. These criteria permit the diagnosis of HVOD when two of the following develop within 2 weeks of BMT: (i) serum bilirubin (SBR) X34 mmol/l, (ii) weight gain of X2.5 percent (%) from pretransplant baseline and (iii) hepatomegaly and/or right upper quadrant pain, in the absence of other causes. We have used rtPA for the treatment of HVOD in our unit since November 1996, and report our experience in 12 consecutive patients.
Patients and treatment
We recorded data from all patients who received rtPA for the treatment of severe HVOD in the Children's Bone Marrow Transplant Unit at Newcastle General Hospital, and the Paediatric Oncology Unit at the Royal Victoria Infirmary from November 1996 to January 2001. HVOD was diagnosed using the Jones criteria 8 namely, jaundice (defined as bilirubin X34 mmol/l) and two of the following three: hepatomegaly (usually painful), ascites, and X5% weight gain from baseline. A conversion factor of 1 mg/dl of SBR equivalent to 17 mmol/l was used. After diagnosis each patient's SBR was plotted daily against the percent weight gain, to predict the course of HVOD based on the Bearman 3 model which compared SBR and weight gain through the post-transplant period in patients with severe or less severe HVOD to those without HVOD. Bearman plotted total SBR against percent weight gain and developed graphs with contour lines to estimate the probability of developing severe HVOD as X30%, X40%, X50% and X60%, at six time intervals post-BMT. If the plotted point was at 0.3 on the contour lines, then the probability of developing severe HVOD was 30%. This model was found to be highly specific and moderately sensitive. 3 Patients who improved with supportive therapy (analgesics and diuretics) only were considered to have mild HVOD and were not included in this study. If a clinical diagnosis of HVOD was considered likely, doppler ultrasonography was performed to look for reversal of hepatic portal venous flow. Usually, only those patients in whom the predicted probability of developing severe HVOD was at least 30%, based on the Bearman 3 model, were started on rtPA (although some patients with rapidly worsening signs were started on treatment before this point was reached) at a dose of 0.05 mg/kg/h for 4 h as an i.v. infusion, once daily for 4 days. If, after 4 days of rtPA therapy, there was no improvement in the severity of HVOD, a second course was given and the dose of rtPA doubled to 0.1 mg/kg/h for 4 h daily, for 4 more days. In cases with partial improvement of HVOD (see definition below) after the first 4 days of therapy, further rtPA was continued at the initial dose for 4 more days. Alongside rtPA, a continuous heparin infusion was commenced with rtPA at a dose of 5 units/kg/h and continued for a total of 10 days.
Full blood count, liver function tests, urea, creatinine, electrolytes and weight were measured daily. Prothrombin time (PT) and activated partial thromboplastin time (APTT) were monitored 6 hourly initially and the dose of heparin adjusted to give an APTT between 1 and 1.5 times the normal value. Blood and Plts infusions were given to keep the Hb concentration above 8 g/dl and Plts numbers above 50 Â 10 9 /l, respectively. Cryoprecipitate was given if the serum fibrinogen decreased below 1 g/dl. Fluid balance was carefully controlled. Full intensive care, including respiratory and circulatory support was given when indicated. Patients were observed for any haemorrhagic complications. Multiorgan failure (MOF) was defined as failure of at least two organ systems. 9 Partial improvement in HVOD was defined as a X10% and consistent decrease in the SBR and/or weight.
Informed consent for bone marrow transplantation was taken from the parent(s) of each patient, and also obtained for the use of rtPA therapy in those children who needed treatment for HVOD.
Scoring system for HVOD
Based on our experience of HVOD we developed a scoring system with the aim of refining the treatment of post-BMT HVOD (Table 1) and then retrospectively applied it to our patients with HVOD. It incorporates the features included in the McDonald 4 and Jones 8 criteria for the diagnosis of HVOD. A rising SBR, hepatomegaly and ascites or weight gain were essential for the diagnosis. We also included a raised PT, the need to regularly transfuse Plts; risk factors for HVOD (raised alanine aminotransferase (ALT) pre-BMT, and/or age less than 6 months at BMT (identified as a risk factor in our patient population)), and associated organ system failure at diagnosis of HVOD. Each parameter was assigned a score of 1 or 2 and a total score was calculated, the maximum possible score being 10 ( Table 1 ). The total score was calculated on a daily basis. Impending HVOD was suggested by the presence of jaundice and hepatomegaly (maximum score 3). Such patients were weighed 6 hourly and the liver function tests checked 12 hourly.
It is important to note that the Jones criteria 8 (or, where used, McDonald 4 criteria) are essential for the diagnosis of HVOD. It is feasible that an individual patient might have a score of greater than 4, while not meeting the essential criteria for the diagnosis of HVOD. Such a patient will not usually be treated with rtPA until an unequivocal diagnosis of HVOD is made. The rationale for the development of this scoring system was specifically to help clinicians to decide when to initiate specific drug therapy after a diagnosis of HVOD had been established.
Statistics
The Mann-Whitney U-test was used to compare the age at BMT in the children who survived with that in those who did not; a similar comparison was made concerning the day on which rtPA treatment was started. Fisher's exact test was used to compare the number of patients with associated organ system failure in survivors and nonsurvivors.
Results
We performed 150 BMTs during the study period of 50 months, 79 (41 allogeneic, 38 autologous) for haematological or oncological, and 71 (70 allogeneic and one autologous) for immunological, indications. A total of 12 patients were given rtPA for HVOD diagnosed on the basis of Jones 8 criteria. Their characteristics are shown in Table 2 . All but three of the patients had immunodeficiency, all but one had an allogeneic BMT and all had received alkylating agents, including busulphan in 10 patients. Busulphan rtPA for hepatic VOD in children RPS Bajwa et al levels were high in two patients requiring a decrease in the dose. Only one patient (case 12) had a high ALT pre-BMT. rtPA was started between days +5 and +19 after BMT and was given for 4-11 days (median 7). Seven patients received a second course of rtPA. The maximum weight gain ranged from 13 to 72% (median 20%); the peak SBR ranged from 21 to 832 mmol/l (median 218). One patient with a peak SBR of only 21 mmol/l had massive hepatomegaly, ascites, weight gain of 19%, and in the absence of evidence of infection or GVHD, was deemed to have anicteric HVOD.
Outcome
(i) Survivors: In 10 patients, the SBR decreased after starting treatment with rTPA. Eight patients survived with Table 1 Scoring system and guide to treatment for HVOD in paediatric BMT patients 1. Progressive and persisting increase in bilirubin: complete resolution of all features of HVOD. Figure 1 shows the dramatic fall in SBR after treatment with rtPA in the eight patients who responded and survived. The other two patients are discussed below in nonsurvivors.
(ii) Nonsurvivors (deaths): Four out of 12 patients died. In two of these, the SBR declined from 232 to 51, and from 574 to 78 mmol/l, after treatment with rtPA, but both eventually died from progressive MOF. Two patients did not respond. In one patient the SBR decreased by 17% after rtPA, but she succumbed with rapidly progressive MOF. The other patient's SBR continued to rise while on treatment with rtPA and peaked at 832 mmol/l; an open liver biopsy confirmed severe HVOD but he bled postoperatively and died. rtPA and heparin had been discontinued more than 2 weeks before liver biopsy. Figure 2 shows the response of bilirubin to rtPA in the four patients who died including two who had responded but died of MOF.
Interventions and complications (Table 3) Five out of 12 patients developed respiratory compromise as a result of massive ascites and needed abdominal paracentesis; the ascitic fluid was drained slowly over 6-12 h and replaced i.v. by 5% albumin solution. After drainage of ascites the respiratory distress settled with oxygen by facial mask in one patient; the other four continued to deteriorate and needed ventilation. Three patients needed peritoneal dialysis for associated renal failure and four needed inotropes to maintain normal circulatory status. In one patient with Omenn's syndrome, pre-existing but mild gastrointestinal bleeding worsened after starting rtPA, she also developed a pulmonary haemorrhage, and hence rtPA was stopped after 7 days, before resolution of HVOD. Subsequently, she developed MOF and died. One patient had mild bleeding from the central venous catheter exit site on day 8 of rtPA treatment, which resolved rapidly with local pressure only. The heparin was stopped in this patient after 8 days of treatment, the course of rtPA having been already completed. There was no other haemorrhagic complication.
In the group of eight patients who survived (Table 3) , the age range was 1-30 months (median 25.5), rtPA was started between days +5 and +19 post-BMT (median +8.5), and was given for 4-9 days (median 6). The maximum SBR ranged from 21 to 408 mmol/ (median 170) and the maximum percent weight gain range was 13-28% (median 19%). The SBR returned to normal between days +8 and +61 post-BMT. None of this group of patients had MOF at the start of rtPA. One patient with neuroblastoma needed inotropes, and abdominal paracentesis to relieve respiratory compromise together with oxygen by facemask, but not ventilation. He made a full recovery with complete resolution of HVOD. No other patient in the surviving group required any invasive intervention in the form of ventilation, abdominal paracentesis, peritoneal dialysis or inotropic support.
In the group of four patients who died (Table 3) , the age range was 2-5 months (median 3.5), rtPA was started between days +5 and +13 post-BMT and given for 7-11 days (median 8.5). The maximum SBR ranged from 218 to 832 mmol/l (median 403) and the maximum percent weight gain ranged from 20 to 72% (median 52%). Two of the four patients had failure of two or more organ systems (including hepatic failure due to HVOD) at the time of starting rtPA; one had respiratory failure and the other had renal failure. Eventually, all four developed respiratory failure needing ventilation, three with renal failure needed peritoneal dialysis and three needed inotropic support for circulatory failure. Three of these four patients had Omenn's syndrome as the primary diagnosis and all three developed capillary leak syndrome (CLS). C1esterase inhibitor concentrate 10 was given in an attempt to treat CLS, without success. Eventually, all four died between days +13 and +58 post-BMT due to MOF.
The difference between the age at BMT of the survivors (who were older) and the nonsurvivors was of borderline statistical significance (P ¼ 0.05). There was no difference in the day on which rtPA was started (P ¼ 0.86). The proportion of survivors who developed renal failure or rtPA for hepatic VOD in children RPS Bajwa et al respiratory failure was significantly less than the proportion of nonsurvivors (P ¼ 0.018 and 0.002, respectively). There was no significant difference in the proportions of survivors and nonsurvivors developing circulatory failure (P ¼ 0.067) and respiratory distress requiring abdominal paracentesis only (P ¼ 1.0) ( Table 3) .
Outcome based on Bearman model and the HVOD scoring system
At the time of starting treatment with rtPA, four of 12 patients had a risk of developing HVOD of p30% by the Bearman model, three had X30 but p40%, and five had X50%. After starting treatment the probability of developing severe HVOD decreased in three patients as they improved; in nine patients it continued to increase reaching 450%, three of these nine died. In two patients the probability of developing severe HVOD was p40% at start of rtPA, then rapidly increased and despite rtPA treatment they rapidly developed severe HVOD with MOF and died. We applied our HVOD scoring system (Table 1 ) to all our patients and then compared the outcome with the Bearman 3 model (Table 4) . As assessed retrospectively, we had started thrombolytic therapy when the HVOD score was X5. At the time of starting rtPA and heparin, one patient had a score of 5, and six scored 7, all seven survived; five patients had a score of X8; four of these died. All the patients who survived had a 30-50% probability of developing severe HVOD using the Bearman 3 model, and all had a score of p7 on our scoring system at start of treatment. Two of the four patients who died had 460% probability of developing severe HVOD and scored 10. The other two had only a 30-40% probability of developing severe HVOD but still deteriorated and died; however, they scored 8 on our scoring system, which appropriately reflected their high-risk status.
Follow-up
Out of the eight patients who were discharged, one subsequently died from relapsed neuroblastoma; he did not have any evidence of sequelae of HVOD at the time of his death. The other seven patients have been followed-up (from 16 to 63 months) and have no sequelae of HVOD.
Discussion
HVOD should be suspected in all patients who develop jaundice, ascites and hepatomegaly in association with weight gain in the first few weeks following BMT. Uniform criteria for the early diagnosis of HVOD are not well established. The Jones 8 criteria are used by some investigators while others have followed the McDonald 4 criteria. By using two of the three McDonald criteria to diagnose HVOD in some studies, it is possible that some patients with mild HVOD may have received thrombolytic or other potentially toxic therapies when they might have improved with supportive care only. Conversely, if there is a delay in starting treatment, MOF may develop. Both of these circumstances are potentially harmful for the patient.
rtPA appears to be more effective in severe HVOD if it is started earlier in the course of the disease, before MOF develops. Miniero 7 analysed retrospectively 51 children treated for HVOD. All 11 of the 51 patients who met only two of McDonald's 4 criteria for the diagnosis of HVOD survived with treatment and 11 out of 40 patients who met three criteria died. In all, 10 of the 12 patients given rtPA 11, 12, 13 have also suggested that the success of thrombolytic therapy for HVOD depends on early treatment, especially before MOF develops. Bearman et al 12 showed that MOF before the start of thrombolytic therapy was an important adverse prognostic factor and that the need for supplemental oxygen, dialysis or mechanical ventilation before start of treatment were associated with lack of response to rtPA treatment. In their study only 12 of 42 patients (29%) with HVOD responded to rtPA and heparin, while this treatment was associated with a significant risk of life-threatening haemorrhages. However, the majority of the patients in Bearman's report 12 were adults with a median age of 38.5 years.
Our experience supports the view that the early institution of rtPA and heparin appears to be an effective treatment of HVOD in paediatric BMT patients. Of 12 patients treated with rtPA and heparin for HVOD, eight survived, seven of whom did not have any other organ system failure (other than hepatic) when HVOD was diagnosed and rtPA started. There was no difference in outcome related to the time of diagnosis of HVOD. Unsurprisingly, the median values of peak SBR, percent weight gain and duration of rtPA therapy were lower in the survivors than the nonsurvivors. Recovery from HVOD was complete and none of the patients had any sequelae of chronic liver disease. The four patients who died either had MOF at start of therapy or developed this complication soon after starting therapy and all eventually died from MOF. Two of these patients had demonstrated partial recovery from HVOD after rtPA, but unfortunately died due to other complications associated with MOF, confirming that in this context MOF is associated with a high morbidity and mortality. We think that these two patients might have recovered from HVOD and survived had we initiated therapy before MOF developed. Thus, overall we had 10 out of 12 patients who demonstrated some response to therapy, although only eight out of these 10 survived.
At what stage after the diagnosis of HVOD should thrombolytic therapy be started?
There seems little doubt that treatment should be started before MOF develops. Bearman 3 suggested that rtPA should only be given to patients whose risk of developing severe HVOD and hence dying exceeded 50%. However, two of our patients died due to MOF even though their risk of developing severe HVOD was only 30-40% at start of rtPA. The different course of our patients may be due to the younger age group or different conditioning regimens used, highlighting the fact that Bearman's model was not specifically intended for application to a paediatric population or to all conditioning regimens. The scoring system we have developed appears to be helpful in answering the above question. A score of 4 suggests early or impending HVOD; at this stage we recommend 12 hourly monitoring of liver function tests and coagulation parameters, careful monitoring of fluid balance with judicious use of diuretics, aiming to avoid intravascular hypovolaemia, and aggressive supportive care, including platelet transfusions when indicated. A score of 5-7 suggests moderate HVOD and thrombolytic therapy should be started. When respiratory compromise develops as a result of ascites, partial drainage of ascitic fluid over 6-12 h using a peritoneal dialysis catheter and careful fluid replacement with i.v. albumin is helpful. A score of 8-10 indicates severe HVOD and a poor prognosis. If after 4 days of therapy, that is, completion of the first course of rtPA treatment, only marginal improvement in HVOD is seen but no toxicity has occurred or is anticipated, then continuation of rtPA for a further 4 days is recommended at a higher dose (see Patients and treatment), or possibly until a steady improvement is seen. However, there are no definitive data to guide the duration of treatment. Alternatives, particularly defibrotide, should be at least considered in such situations. The scoring system appears to identify high-risk patients at an earlier stage and so may facilitate prompt identification and treatment of such patients before MOF develops, and thus improve survival. It may also help identification of those patients who will only develop mild HVOD and may improve with supportive therapy alone. However, this scoring system was developed and then evaluated retrospectively to a group of patients that largely comprised children with immunodeficiencies, who may have differing risk factors for HVOD. It therefore requires prospective evaluation in a larger group of children with a wider range of primary diagnoses.
A raised alanine aminotransferase concentration pre-BMT appears to be a risk factor for the development of HVOD.
14 Although not previously reported our experience suggests that age and the indication for BMT may also be important risk factors for the development and severity of HVOD. In our study all the patients who died were o6 months age; three of these had Omenn's syndrome.
In our experience, attempts to confirm the diagnosis of HVOD histologically by liver biopsy were unrewarding and led to a high risk of death from haemorrhage even in the absence of rtPA treatment. Only two of the 12 patients suffered bleeding following rtPA therapy; one of these had worsening of pre-existing gastrointestinal bleeding and then a pulmonary haemorrhage, while the other had only a minor superficial bleed. Careful monitoring of PT, APTT, fibrinogen and adjustment of the heparin infusion rate if needed, decreases the risk of life-threatening haemorrhage associated with rtPA therapy.
Recently, antithrombin-III (AT-III) 15 and defibrotide 6 have been used for the treatment of HVOD. AT-III is a naturally occurring anticoagulant and is decreased in BMT patients. Treatment with AT-III 15 reduced the probability of death from chemotherapy-induced HVOD and organ dysfunction following BMT. However, there is very little information available in paediatric BMT patients. Defibrotide is a polydeoxyribonuceotide derived from mammalian tissue. It causes stimulation of thrombomodulin synthesis, an increase in endogenous tissue plasminogen activator, and a decrease in plasminogen activator inhibitor type 1 (PAI 1). It has been shown to be effective in cases where rtPA has failed. 6 Defibrotide appears to be safer than rtPA as it does not have a systemic anticoagulant effect (in contrast to rtPA). However, further research is needed to prove its efficacy and to clarify the optimal dose schedule, especially in paediatric practice. Nevertheless, if it is proven to be effective, defibrotide is likely to become the treatment of choice in the near future. While awaiting more effective therapy, there is a need to develop more sensitive and specific laboratory parameters to facilitate an early diagnosis and hence prompt commencement of treatment of HVOD, before MOF has developed. Serum aminopropeptide of type III procollagen 16, 17 and PAI 1 18 appear to be increased in patients with HVOD. Further studies of these measurements are needed to establish their status as potential serum markers for HVOD in children.
There is also a need to redefine the severity of HVOD. It is accepted that a patient with HVOD who improves with supportive therapy only (including diuretics and analgesics) should be considered to have mild HVOD. We suggest that a patient who requires specific therapy (eg rtPA and heparin, or defibrotide), but who does not develop MOF, should be considered to have moderate HVOD; while a patient who needs intensive care such as ventilation, dialysis, inotropes or drainage of ascites has severe HVOD. The most logical critical factor defining the severity of HVOD appears to be the development of MOF. Such prospective grading of severity appears to be more reflective of the patient's status while being treated for HVOD than the current retrospective definition of HVOD.
We conclude that HVOD is a life threatening but potentially treatable complication following BMT, and that the development of MOF in patients with HVOD is a poor prognostic factor. Infants less than 6 months age are at high risk of developing severe HVOD. In paediatric practice, as in adults, rtPA and heparin therapy appear to improve the outcome, if started early in the course of the disease, that is, before the development of MOF. Although toxicity was acceptable in this study, rtPA should be used with great care in view of the risk of potentially serious haemorrhage in these susceptible patients. There is no published comparison yet between the use of rtPA and newer, possibly safer, alternatives such as defibrotide. However once MOF has developed, the prognosis is poor in spite of treatment. A scoring system for HVOD in children is presented to facilitate the decision to commence treatment at an early stage.
